Management

Tarveda has built a team of innovative and successful drug developers whose deep collective experience spans drug discovery, research, and development at leading biotechnology and pharmaceutical companies.

Drew FromkinDrew Fromkin has more than 29 years of leadership experience in major areas of the healthcare industry, including biopharmaceuticals, life sciences and healthcare services sectors. He has an accomplished track record leading public and private companies through all stages of growth. Prior to Tarveda Therapeutics, Mr. Fromkin served as President, CEO and Director of Clinical Data, Inc. (NASDAQ: CLDA) where he transformed the Company from a traditional diagnostics business with a sub-$100 million market capitalization to an innovative biopharmaceutical and personalized medicine company. Clinical Data was acquired for $1.2 billion by Forest Laboratories and he has since served in roles as an advisor, consultant or director to a variety of healthcare ventures. Prior to Clinical Data, Mr. Fromkin served as President and CEO of DoctorQuality, Inc. (acquired by Quantros, Inc.), President, CEO and Director of Endo Surgical Devices, Inc. and Corporate Vice President, Business Development, for Merck-Medco, a wholly-owned subsidiary of Merck & Co. Mr. Fromkin began his career at Health Information Technologies, Inc. as General Manager of their subsidiary, MCA, and Director of Marketing and Payer Alliances for the parent company. He currently serves as a director and Chair of the compensation committee for Tobira Therapeutics (TBRA). Mr. Fromkin was named to Business Week's "CEOs 40 and Under" list while at Clinical Data. Mr. Fromkin holds a B.A. from Brandeis University.

Leila Alland, M.D.

Leila Alland joined Tarveda Therapeutics as Chief Medical Officer in January 2016. Dr. Alland has broad experience as a clinical leader developing both small and large molecule oncology products including Doxil®, Pegintron®, Tasigna®, and Opdivo®.  Dr. Alland most recently served as Vice President and Head of Oncology Early Clinical Development at AstraZeneca where she was instrumental in building a new Oncology Early Clinical Development unit in Boston, MA, and Cambridge, UK. At AstraZeneca, she led numerous clinical stage programs through Phase 1/2 development, including six first-in-human programs and a Phase 2 registration study supporting the approval of Tagrisso™. At BMS, Dr. Alland served as clinical head for multiple early phase oncology programs spanning tumor targeted and immuno-oncology therapies. Dr. Alland conducted her pediatric hematology and oncology training at Memorial Sloan Kettering Cancer Center and then joined the faculty of the Albert Einstein College of Medicine as Assistant Professor where her cancer biology research resulted in publications in Nature, Nature Genetics and Cell.  She received her medical degree at New York University School of Medicine and her B.A. in Biology at the University of Pennsylvania.

Richard Wooster

Richard Wooster is President of Research & Development at Tarveda and has three decades of experience in cancer genetics and pharmaceutical drug discovery and development. Previously, he was Vice President and Head of the Cancer Metabolism Discovery Performance Unit in Oncology at GlaxoSmithKline. In this role, he led the evaluation of the metabolic pathways that are deregulated in cancer, led the PI3K portfolio of inhibitors in Oncology at GSK and was responsible for the clinical evaluation of the novel antimitotic kinase inhibitors to PLK and CENPE. Before this, Dr. Wooster led the translational medicine group in Oncology at GSK and worked on Tykerb®, Mekinist® and Tafinlar®. During his academic career, Dr. Wooster discovered the breast cancer susceptibility gene BRCA2, was one of the founders of the Cancer Genome Project at the Welcome Trust Sanger Institute where, among many achievements, mutations in BRAF were first discovered and he developed the COSMIC mutation database and website. He has more than 100 peer-reviewed articles and papers in scientific journals. Dr. Wooster has a First Class BSc in Biochemistry and a PhD in drug metabolizing enzymes, both from the University of Dundee, Scotland.

Mark Bilodeau

Mark Bilodeau is Senior Vice President of Chemistry at Tarveda, with more than 20 years of experience in medicinal chemistry and drug discovery. Previously, he was Senior Director of Medicinal Chemistry at Merck & Co. Inc., where he developed a broad background in drug discovery for the oncology, pain, neuroscience, ophthalmology, and cardiovascular therapeutic areas. While at Merck, Dr. Bilodeau was an inventor and team leader on seven molecules that advanced into clinical testing and also led a development team that brought one molecule from discovery through Phase I clinical testing. Dr. Bilodeau received a B.S. in Chemistry from Boston College and a Ph.D. in Organic Chemistry from Harvard University. He conducted postdoctoral studies at the Memorial Sloan-Kettering Cancer Center.

Sudha Kadiyala, PhD

Sudha Kadiyala is the Senior Vice President of Strategy & Development at Tarveda with 20 years of experience in the biotechnology industry. Previously, he worked at ATRM, a Johnson & Johnson company, with dual responsibilities as Senior Director of Product Development and Senior Director of Business Development & Strategic Planning.  During his 13 years at Johnson & Johnson, he served in various management roles in R&D and general management, including as Interim Head of Johnson & Johnson Regenerative Therapeutics, LLC.  Earlier in his career, Dr. Kadiyala held R&D management roles at Osiris Therapeutics, an adult stem cell company. He received a B. Technology from IIT, Bombay, a Masters of Engineering from Thayer School of Engineering at Dartmouth College and a PhD from the Johns Hopkins School of Medicine.

Mary Simcox, Ph.D.

Mary Simcox joined Tarveda as Vice President of Biology in January 2016. Dr. Simcox brings to Tarveda more than 10 years of experience in cancer cell biology and pharmaceutical drug discovery and development, including her most recent role as Director of Biology for FORMA Therapeutics as well as previous senior R&D roles at Roche in cancer signaling, preclinical angiogenesis and Avastin® biomarkers.  Her undergraduate and doctoral work were completed at the University of California at Davis.